New York State Common Retirement Fund Boosts Stake in IQVIA Holdings Inc. (NYSE:IQV)

New York State Common Retirement Fund lifted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,480 shares of the medical research company's stock after buying an additional 1,958 shares during the period. New York State Common Retirement Fund owned approximately 0.06% of IQVIA worth $18,420,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Continuum Advisory LLC boosted its position in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after acquiring an additional 64 shares in the last quarter. Ballentine Partners LLC boosted its position in IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after acquiring an additional 69 shares in the last quarter. ST Germain D J Co. Inc. boosted its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. Zions Bancorporation N.A. boosted its position in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its position in IQVIA by 10.7% during the 4th quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after acquiring an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $2.37 during midday trading on Friday, hitting $160.88. The company had a trading volume of 2,312,787 shares, compared to its average volume of 1,678,075. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. The company has a market cap of $27.83 billion, a price-to-earnings ratio of 21.92, a PEG ratio of 1.78 and a beta of 1.30. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a fifty day moving average of $152.90 and a two-hundred day moving average of $170.67.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the prior year, the firm earned $2.54 EPS. The business's revenue was up 2.5% on a year-over-year basis. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on IQV. Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Mizuho dropped their price target on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. JPMorgan Chase & Co. dropped their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and dropped their price target for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Finally, Truist Financial dropped their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $222.45.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.